SC
RXRX icon

Slow Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Slow Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,400
Closed -$9.34K – 157
2023
Q1 		$9.34K Buy
+1,400
New +$11.1K ﹤0.01% 156

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Slow Capital's RXRX Position: Q2 2023 in Review

Slow Capital sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 1,400 shares — an estimated $9.34K sold.

Slow Capital first reported a position in RXRX in Q1 2023 and held it in 1 quarter. The position peaked at $9.34K in Q1 2023. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

  • Slow Capital reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Slow Capital sold 1,400 Recursion Pharmaceuticals shares in Q2 2023, an estimated $9.34K.
  • Slow Capital first reported a position in Recursion Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Slow Capital's Recursion Pharmaceuticals position peaked at $9.34K in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Slow Capital's 13F filing for Q2 2023, filed 9 Aug 2023.